On Mar. 23, 2020, Harvard Bioscience announced that it had launched an innovative technology – known as Accumulated Inhaled Aerosol (AIA) – for academic researchers, contract research organizations (CROs) and pharmaceutical companies involved in pre-clinical inhalation and exposure studies.

With the new Buxco AIA system, researchers are presented with real-time aerosol amounts inhaled and deposited in subjects’ lungs, a breakthrough improvement over the current delivered dose measurement. By reporting those measures against real-time respiratory endpoints using FinePointe software, researchers can observe a direct correlation between dose and lung function over time.

Integrating exposure and respiratory capabilities, this system delivers precise amounts of various aerosols to multiple subjects in a uniform, and reproducible manner, then measures pulmonary effects from the same platform. This technology and other new advancements in the Harvard Bioscience inhalation platform provide researchers with novel tools to study COVID-19 and advance development in both the discovery of new therapies and the pre-clinical regulatory phases, as solutions progress toward general clinical use.